Insider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,118 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 1,118 shares of Surrozen stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $19.87, for a total value of $22,214.66. Following the sale, the vice president owned 16,091 shares in the company, valued at $319,728.17. This represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Surrozen Trading Up 3.0%

SRZN traded up $0.57 during trading on Tuesday, reaching $19.67. The stock had a trading volume of 78,574 shares, compared to its average volume of 85,990. The company has a market capitalization of $168.57 million, a price-to-earnings ratio of -0.88 and a beta of 0.58. The stock’s 50 day moving average is $17.64 and its two-hundred day moving average is $13.39. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94.

Surrozen (NASDAQ:SRZN) last released its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The business had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities research analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Hedge Funds Weigh In On Surrozen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRZN. Citadel Advisors LLC boosted its stake in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Surrozen during the third quarter valued at $621,000. Armistice Capital LLC bought a new stake in Surrozen in the 2nd quarter worth about $536,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Surrozen in the 3rd quarter worth about $889,000. 66.57% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SRZN has been the subject of several recent research reports. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.